Fresenius/€FRE
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Fresenius
Fresenius SE & Co. KGaA, operating under the ticker FRE, is a global healthcare group founded in 1912. The company specializes in products and services for dialysis, hospitals, and outpatient medical care. Operating in the healthcare sector, Fresenius provides a range of services including engineering and services for hospitals and other healthcare facilities.
Ticker
€FRE
Sector
Primary listing
XETRA
Employees
176,207
Headquarters
Website
Fresenius Metrics
BasicAdvanced
€28B
24.76
€2.00
1.01
€1.00
2.02%
Price and volume
Market cap
€28B
Beta
1.01
52-week high
€49.96
52-week low
€31.60
Average daily volume
41K
Dividend rate
€1.00
Financial strength
Current ratio
1.312
Quick ratio
0.637
Long term debt to equity
55.939
Total debt to equity
67.849
Dividend payout ratio (TTM)
58.31%
Interest coverage (TTM)
3.79%
Profitability
EBITDA (TTM)
2,610
Gross margin (TTM)
24.28%
Net profit margin (TTM)
5.05%
Operating margin (TTM)
8.41%
Effective tax rate (TTM)
28.97%
Revenue per employee (TTM)
€130,000
Management effectiveness
Return on assets (TTM)
2.76%
Return on equity (TTM)
5.83%
Valuation
Price to earnings (TTM)
24.762
Price to revenue (TTM)
1.251
Price to book
1.53
Price to tangible book (TTM)
19.26
Price to free cash flow (TTM)
22.539
Free cash flow yield (TTM)
4.44%
Free cash flow per share (TTM)
2.194
Dividend yield (TTM)
2.02%
Forward dividend yield
2.02%
Growth
Revenue change (TTM)
4.32%
Earnings per share change (TTM)
-200.90%
3-year revenue growth (CAGR)
-9.21%
10-year revenue growth (CAGR)
-1.51%
3-year earnings per share growth (CAGR)
-11.55%
10-year earnings per share growth (CAGR)
-0.73%
3-year dividend per share growth (CAGR)
2.82%
10-year dividend per share growth (CAGR)
8.56%
What the Analysts think about Fresenius
Analyst ratings (Buy, Hold, Sell) for Fresenius stock.
Bulls say / Bears say
Fresenius increased its 2025 organic revenue growth target to 5–7%, up from 4–6%, following stronger-than-expected results in the first half under its #FutureFresenius plan (Reuters)
In Q2/2025, Fresenius posted EBIT (before special items) of €654 million, surpassing analysts’ consensus by 2.6%, with solid performance from Fresenius Kabi and Helios (Reuters)
After the raised forecast and Q2 beat, Fresenius shares rose 2.6% in early Frankfurt trading, showing investors’ positive reaction to the company’s clearer portfolio and growth prospects (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Sept 2025.
Fresenius Financial Performance
Revenues and expenses
Fresenius Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fresenius stock?
Fresenius (FRE) has a market cap of €28B as of October 29, 2025.
What is the P/E ratio for Fresenius stock?
The price to earnings (P/E) ratio for Fresenius (FRE) stock is 24.76 as of October 29, 2025.
Does Fresenius stock pay dividends?
Yes, the Fresenius (FRE) stock pays dividends to shareholders. As of October 29, 2025, the dividend rate is €1 and the yield is 2.02%. Fresenius has a payout ratio of 58.31% on a trailing twelve-month basis.
When is the next Fresenius dividend payment date?
The next Fresenius (FRE) dividend payment date is unconfirmed.
What is the beta indicator for Fresenius?
Fresenius (FRE) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.